Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;13(5):983-993.
doi: 10.1007/s13300-022-01245-9. Epub 2022 Mar 22.

Impact of My Dose Coach App Frequency of Use on Clinical Outcomes in Type 2 Diabetes

Ambika Gopalakrishnan Unnikrishnan  1 , Vijay Viswanathan  2 , Fang Liz Zhou  3 , Lichen Hao  3 , Prithvi Kamath  4 , Monica Bertolini  3 , Jose Fernando Botero  5 , Leonardo Mancillas-Adame  6
Affiliations

Impact of My Dose Coach App Frequency of Use on Clinical Outcomes in Type 2 Diabetes

Ambika Gopalakrishnan Unnikrishnan et al. Diabetes Ther. 2022 May.

Abstract

Introduction: My Dose Coach (MDC) is a US Food and Drug Administration-approved digital smartphone application designed to help users with type 2 diabetes (T2D) titrate their basal insulin (BI) according to a clinician-prescribed individualized titration plan. The aim of this analysis was to assess the impact of the frequency of MDC use on clinical outcomes.

Methods: This retrospective observational analysis included people with T2D who were registered for MDC (August 1st, 2018-April 30th, 2020) and received BI. Users with an activated care plan and ≥2 fasting blood glucose (FBG) observations spanning ≥2 weeks were defined as active. Outcomes included percentage achieving their individual FBG target, time to FBG target, change in FBG, change in insulin dose and hypoglycemia. Users were stratified into high (>3 days per week), moderate (>1- ≤3 days per week), and low (≤1 day per week) MDC usage groups.

Results: The analysis included 2517 active MDC users. Approximately 49% of users had high MDC usage. Overall, 44% of users across all usage frequencies achieved their individual FBG target. High MDC use was associated with significantly better FBG target achievement and less time to FBG target versus moderate- and low-usage groups (p≤0.01 for all). Insulin dose change was significantly greater in the high- versus moderate-usage group (p=0.01). There was no significant difference in hypoglycemia incidence among MDC usage groups (12%-16% of users in any usage group).

Conclusions: More frequent MDC usage was associated with better FBG outcomes without increased hypoglycemia risk.

Keywords: Glycemic control; Mobile application; Self-management; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study disposition. FBG fasting blood glucose, MDC My Dose Coach
Fig. 2
Fig. 2
FBG target achievement by MDC usage and stratified by titration duration. FBG fasting blood glucose, MDC My Dose Coach
Fig. 3
Fig. 3
Time to FBG achievement by MDC usage and stratified by titration duration. FBG fasting blood glucose, MDC My Dose Coach, SD standard deviation
Fig. 4
Fig. 4
FBG change by MDC usage groups: A overall and stratified by titration duration (B  ≤4 weeks; C  >4 weeks). FBG fasting blood glucose, MDC My Dose Coach, SD standard deviation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73–S84. - PubMed
    1. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in Type 2 Diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study) Diabetes Care. 2019;42:416–426. doi: 10.2337/dc17-1144. - DOI - PMC - PubMed
    1. Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20:427–437. doi: 10.1111/dom.13088. - DOI - PMC - PubMed
    1. International Diabetes Federation. IDF Diabetes Atlas, Ninth edition. 2019. https://www.diabetesatlas.org/en/. Accessed 19 May 2021
    1. Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19:1155–1164. doi: 10.1111/dom.12927. - DOI - PMC - PubMed

LinkOut - more resources